Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.65 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.62 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.61 |
| ▸ | NUAK2 | Q9H093 | 2/20 | 0.56 |
| ▸ | JAK3 | P52333 | 2/20 | 0.56 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.55 |
| ▸ | JAK2 | O60674 | 1/20 | 0.54 |
| ▸ | JAK1 | P23458 | 1/20 | 0.54 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18018946 | 0.92 | NUAK2 (0.67) | EGFRPTK2NUAK2JAK3NUAK1 | |
| SCHEMBL18018967 | 0.89 | MAP3K7 (0.79) | EGFRPTK2MAP3K7NUAK2JAK3 | |
| SCHEMBL18018787 | 0.88 | MAP3K7 (0.77) | EGFRPTK2MAP3K7JAK3JAK2 | |
| SCHEMBL18018878 | 0.82 | EGFR (0.79) | EGFRPTK2MAP3K7JAK3NUAK1 | |
| SCHEMBL10127995 | 0.81 | EGFR (0.80) | EGFRPTK2MAP3K7NUAK2JAK3 | |
| SCHEMBL18018943 | 0.79 | EGFR (0.69) | EGFRPTK2NUAK2JAK3NUAK1 | |
| SCHEMBL18018873 | 0.79 | MAP3K7 (0.68) | EGFRPTK2MAP3K7JAK3JAK2 | |
| SCHEMBL18018877 | 0.79 | MAP3K7 (0.81) | EGFRPTK2MAP3K7JAK3JAK2 | |
| SCHEMBL30399030 | 0.78 | PTK2 (0.70) | EGFRPTK2 | |
| SCHEMBL29024144 | 0.78 | PTK2 (0.70) | EGFRPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-22 | — | — | US | disclosed |
| EP-3778605-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3778604-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | Dana Farber Cancer Institute, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-02-09 | — | — | US | disclosed |
| WO-2016130920-A2 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-08-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115055-A1 | LRRK2 INHIBITORS AND METHODS OF MAKING AND USING THE SAME | LRRK2, PARK7, PINK1 | EGFR 2819/4885PTK2 574/4885MAP3K7 166/4885 |
| US-10913744-B2 | LRRK2 inhibitors and methods of making and using the same | LRRK2, PARK7, PINK1 | EGFR 2819/4885PTK2 574/4885MAP3K7 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.